MITHRA PHARMACEUTICALS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.216 EUR | -1.82% |
|
-3.57% | -82.78% |
| Apr. 22 | Mithra Pharmaceuticals Obtains Court Protection Measures | MT |
| Mar. 08 | Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 752.8 | 989.7 | 841.5 | 880.1 | 186.5 | 14.93 | 14.93 | - |
| Enterprise Value (EV) 1 | 721 | 1,138 | 1,008 | 1,201 | 486.3 | 396.8 | 181.4 | 227.7 |
| P/E ratio | -60.6 x | -37.5 x | -8.76 x | -7.43 x | -2.79 x | -0.16 x | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11.5 x | 10.3 x | 93.2 x | 38.8 x | 2.78 x | 2.16 x | 0.34 x | 0.27 x |
| EV / Revenue | 11 x | 11.8 x | 112 x | 53 x | 7.26 x | 9.88 x | 4.13 x | 4.1 x |
| EV / EBITDA | 18.8 x | 35.8 x | -13.7 x | -15.5 x | -34 x | -7.52 x | -6.13 x | 6.78 x |
| EV / FCF | -111 x | -19.6 x | -11.1 x | -14 x | -5.9 x | -26.9 x | -7 x | 4.55 x |
| FCF Yield | -0.9% | -5.09% | -9% | -7.15% | -17% | -3.72% | -14.3% | 22% |
| Price to Book | 4.99 x | 6.29 x | 5.33 x | 25.6 x | 5.69 x | 0.44 x | - | - |
| Nbr of stocks (in thousands) | 37,639 | 37,689 | 42,714 | 44,051 | 54,764 | 69,108 | 69,108 | - |
| Reference price 2 | 20.00 | 26.26 | 19.70 | 19.98 | 3.405 | 0.2160 | 0.2160 | 0.2160 |
| Announcement Date | 3/1/19 | 3/9/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/8/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 65.46 | 96.5 | 9.03 | 22.67 | 67 | 40.16 | 43.9 | 55.5 |
| EBITDA 1 | 38.31 | 31.82 | -73.81 | -77.45 | -14.3 | -52.77 | -29.6 | 33.6 |
| EBIT 1 | 35.46 | 34.97 | -79.94 | -87.88 | -26.24 | -139.1 | -47.7 | -28 |
| Operating Margin | 54.16% | 36.24% | -885.32% | -387.66% | -39.17% | -346.49% | -108.66% | -50.45% |
| Earnings before Tax (EBT) 1 | -16.23 | -40.35 | -110.9 | -123.8 | -11.48 | -161.8 | - | - |
| Net income 1 | -12.36 | -26.6 | -92.09 | -116.9 | -59.62 | -173.5 | -55.4 | -8.7 |
| Net margin | -18.88% | -27.56% | -1,019.78% | -515.59% | -88.99% | -432.08% | -126.2% | -15.68% |
| EPS 2 | -0.3300 | -0.7000 | -2.250 | -2.690 | -1.220 | -1.390 | - | - |
| Free Cash Flow 1 | -6.467 | -57.94 | -90.67 | -85.87 | -82.48 | -9.4 | -25.9 | 50.1 |
| FCF margin | -9.88% | -60.05% | -1,004.1% | -378.82% | -123.11% | -25.79% | -59% | 90.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 149.11% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 3/9/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/8/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 |
|---|---|
| Net sales 1 | 7.035 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -50.47 |
| Net margin | -717.4% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 9/26/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 149 | 167 | 321 | 300 | 310 | 167 | 213 |
| Net Cash position 1 | 31.8 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 4.671 x | -2.256 x | -4.141 x | -20.96 x | -5.876 x | -5.625 x | 6.333 x |
| Free Cash Flow 1 | -6.47 | -57.9 | -90.7 | -85.9 | -82.5 | -9.4 | -25.9 | 50.1 |
| ROE (net income / shareholders' equity) | -10.4% | 10.1% | -43.5% | -96.8% | -177% | -6,827% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.010 | 4.170 | 3.690 | 0.7800 | 0.6000 | 0.4900 | - | - |
| Cash Flow per Share 2 | 0.0900 | -1.240 | -1.950 | -1.710 | -1.160 | -0.2000 | -0.4000 | -0.3000 |
| Capex 1 | 10 | 11.1 | 10.6 | 11.5 | 25.7 | 9.4 | 9.4 | 9.4 |
| Capex / Sales | 15.29% | 11.52% | 117.88% | 50.66% | 38.3% | 25.79% | 21.41% | 16.94% |
| Announcement Date | 3/1/19 | 3/9/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/8/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
0.216
EUR
Average target price
0.11
EUR
Spread / Average Target
-49.07%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -82.78% | 15.94M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- MITRA Stock
- Financials Mithra Pharmaceuticals S.A.
